Clinical trial · Interventional
Angiogenic Switch in Patients With Colorectal Cancer
Angiogenic Switch as Predictor of Response to Chemotherapy in Patients With Metastatic Colorectal Cancer
NCT02075086CI-TRIAL-00017148ANGIOSWITCHunknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A group of colorectal cancer (CRC) patients treated with chemotherapy and Bevacizumab (Bev) maintain the same sensitivity after progression to maintenance treatment because they remain dependent on VEGF angiogenic mediator, while other patients in whom there is an angiogenic switch (AS) become dependent on other angiogenic cytokines and become resistant to Bev chemotherapy combinations .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Xelox or Xeliri Bevacizumab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Chemotherapy treatment
- description
- Chemotherapy treatment with Xelox or Xeliri and bevacizumab
- interventionNames
- Drug: Xelox or Xeliri Bevacizumab
Primary outcomes (1)
- measure
- Progression Free Survival
- timeFrame
- 1 year
- description
- Days from cycle one day one to progression
Secondary outcomes (1)
- measure
- Feasibility
- timeFrame
- 2 years
- description
- Feasibility of doing a clinical prospective trial with a measure od plasma citoquines.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of stage IV colorectal adenocarcinoma. * Age ≥ 18 years . * Measurable disease by RECIST criteria. * Life expectancy ≥ 6 months. * Candidate to receive treatment with first-line chemotherapy. * Availability of tumor tissue. Exclusion Criteria: * Patients who have received prior treatment with first-line chemotherapy for metastatic disease. * Patients in whom there is contraindication to the administration of either drug used in the study: capecitabine, irinotecan, oxaliplatin or Bev. * Patients receiving anticoagulant oral treatment. * Patient with diagnosis of other malignancies within 5 years prior to diagnosis except basal cell carcinoma or cervical carcinoma · in situ. · The inclusion of patients with malignant disease diagnosed more than 5 years ago without recurrence in the previous 3 years will be analyzed individually * Patients with bone disease as the only manifestation of the disease.
References
Publications (0)
Data not yet available
No reference posted for this study.